



QCDx LLC - EXECUTIVE SUMMARY

About

- ◆ QCDx LLC is an early stage, medical device company developing the **RareScope™ novel platform to detect Circulating Tumor Cells (CTCs) early, when cancer can be cured.**
- ◆ Founded and led by **Dr. Triantafyllos Tafas** QCDx is built on a 25+ year history in development and commercialization of cancer RUO and diagnostic IVD & LDT products to major US and EU labs that have been used in more than 300,000 cancer diagnostic tests over the past 10 years.
- ◆ QCDx will commercialize products as **Research Use Only (RUO)** in the cancer research, pharma, CRO and biotech markets, followed by submission for **IVD approval by the FDA.**

Technology & Products

- ◆ The **RareScope™ Fluorescence Light Sheet Microscope** offers **sensitive** detection of **intact and live CTCs** from multiple phenotypes **without enrichment.**
- ◆ **RarePicker™ micromanipulation** will isolate **intact/live** cells for **single cell analysis**, including genomic, transcriptomic, epigenetic and proteomic.
- ◆ The **RareVivo™ specimen chamber** allows **ex vivo imaging** of cells while perfused with media in a **3D continuous culture.** This opens the path for **evaluation of cancer drugs on CTCs** and white blood cells **before they are administered to the patient.**
- ◆ The **RareScope** will be used in two validation studies: 1) **breast cancer diagnostic** clinical study with the UCONN NEAG Cancer Center (patient enrollment in April 2020) and 2) the Duke Brain Cancer Center study for CTC **detection in metastatic glioblastoma** (3Q 2020).


Liquid Biopsy Market

- ◆ QCDx's products will be launched in the **US \$1.4 billion liquid biopsy market^(*)** and then to the Global liquid biopsy market projected to grow to \$9.6 billion by 2026.
- ◆ **First \$240,000 sale** to the **University of Connecticut Cancer Center** closed after just 2 years of operation and about \$0.5 million of convertible note investment. Other cancer research and clinical early adopters include **Jackson Laboratories.**

Competition

- ◆ Existing **commercial CTC liquid biopsies** (e.g. CellSearch, RareCyte, Fluidigm, Cynvenio etc) use **enrichment** for CTC detection in patient blood. No system offers **ex vivo** cell imaging.



 Liquid biopsies of **ctDNA** (Grail, Foundation Medicine, Genomic Health, Guardant Health, Trovogene) are **growing fast for cancer screening and clinical trial applications** by analyzing genomic information released in patient blood from dying cancer cells.



Corporate and Scientific Advisory Board

- ◆ **Corporate Board** composed of Founders **Dr. Triantafyllos Tafas**, (CEO) & **Harry H. Penner** (Chairman, strategic biotech executive, entrepreneur), **Dr. Kenneth Kaitin** (Director, Center for Study of Drug Development, Tufts University) and **Dr. Liming Shao** (Board Advisor, Center for Study of Drug Development, Fudan University, China).
- ◆ **Scientific Advisory Board is composed of luminaries in their fields** includes **Dr. George Church** (Harvard University, MIT), **Sir Walter Bodmer** (Oxford University, world acclaimed cancer biologist), **Dr. Susan Tannenbaum** (UConn Cancer Center, Chief of Oncology) and **Dr. Enrique Ballesteros** (Chief UConn Clinical Pathology).

Intellectual Property

- ◆ International application PCT/US2018/39660, “QUANTITATIVE LIQUID BIOPSY DIAGNOSTIC SYSTEM AND METHODS”, 27 June 2018 [Priority date 27 June, 2017]
- ◆ International Application PCT/US2019/049244, “BIOLOGICAL SAMPLE HOLDER AND HANDLER”, 26 June 2019 [Priority date 27 June, 2018]

Investment Opportunity

- ◆ Comparable players in the space have raised significant capital including EPIC Sciences (CA, \$152M), Fluidigm (CA, 125M), RareCyte (WA, \$52M), Biocept (CA, \$43M). **QCDx has delivered tangible milestones at a small fraction of the cost** utilizing small institutional investment and founder’s capital only.
- ◆ QCDx is raising **Seed Series** financing, with substantial use of funds toward building our **executive management team**, enhancing **Intellectual Property**, developing **RareScope AI** and **software engine, engineering design** and **manufacturing**, advancing **validation studies** with breast and glioblastoma patients and building **marketing and sales** actions for **RareScope launch** in the **US and International markets**.
- ◆ For further details around our Seed Series financing please contact:
 - Triantafyllos (Fyl) Tafas: fyl.tafas@qcd-x.com
www.qcd-x.com

Sources: (*) Global Market Insights, 2019
(**) Transparency Market Research, 2019